Oncology – Urological
Review: Recent Advances in the Management of Metastatic Prostate Cancer
1 Oct, 2021 | 09:55h | UTCRecent Advances in the Management of Metastatic Prostate Cancer – JCO Oncology Practice
Clinical Review on the Management of Metastatic Renal Cell Carcinoma.
26 Sep, 2021 | 21:41h | UTCClinical Review on the Management of Metastatic Renal Cell Carcinoma – JCO Oncology Practice
Cohort study: Half of men with low-risk prostate cancer move from surveillance to treatment within a few years.
27 Aug, 2021 | 08:26h | UTC
RCT: New blood test could improve prostate cancer screening.
17 Aug, 2021 | 08:48h | UTCProstate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
News release: New blood test improves prostate cancer screening – Karolinska Institutet
Related:
RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
Commentary on Twitter
Online first: #Prostatecancer #screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial #pcsm https://t.co/bijoJk8RbK pic.twitter.com/ENWEjqG3Kr
— The Lancet Oncology (@TheLancetOncol) August 13, 2021
Study: many patients with small renal masses can be safely managed with active surveillance.
2 Aug, 2021 | 00:07h | UTCCommentary: More Data Support Active Surveillance for Small Renal Masses — Most patients avoided surgery with no metastasis, better focus on aggressive disease – MedPage Today (free registration required)
RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
9 Jul, 2021 | 10:03h | UTCMRI-Targeted or Standard Biopsy in Prostate Cancer Screening – New England Journal of Medicine (link to abstract – $ for full-text)
News release: MRI can cut overdiagnoses in prostate-cancer screening by half – Karolinska Institutet
Related articles: RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer AND Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer AND Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis AND Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer AND Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer AND Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy AND Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer AND Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis AND Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer
RCT: Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer.
24 Jun, 2021 | 09:41h | UTCLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: Adjuvant Nivolumab vs. Placebo in Muscle-Invasive Urothelial Carcinoma.
3 Jun, 2021 | 10:36h | UTC
AUA Guideline | Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up.
2 Jun, 2021 | 08:27h | UTCCommentary: AUA updates guideline on renal masses and localized renal cancer – Urology Times
M-A: A biofeedback‐guided program or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy.
26 May, 2021 | 08:13h | UTC
RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.
10 May, 2021 | 00:46h | UTC18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link to abstract – $ for full-text)
Final Survival Analysis: Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer
4 May, 2021 | 08:26h | UTC
Commentary on Twitter
Just in JCO @ASCO 👉Glad to share final OS data from TITAN trial after ~4 yrs of follow up: unprecedented OS benefit with APALUTAMIDE/ APA after adjusting for crossover from placebo👉48% reduction in risk of death with APA, HR=0.52 👇https://t.co/9ZCoXsTE6x @oncoalert @urotoday pic.twitter.com/FNBFA84DxY
— Neeraj Agarwal (@neerajaiims) April 29, 2021
AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies
29 Apr, 2021 | 08:33h | UTCNews release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association
Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association
Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review
18 Apr, 2021 | 21:16h | UTC
M-A: Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy
18 Apr, 2021 | 21:14h | UTC
RCT: Better continence after 3 months with robotic-assisted compared with laparoscopic radical prostatectomy
18 Apr, 2021 | 21:11h | UTCRobotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01) – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01)https://t.co/YenifaBnfe@doguteber @Hohenfellner pic.twitter.com/kfpQc1u0xf
— European Urology (@EUplatinum) February 11, 2021
RCT: Nivolumab plus Cabozantinib vs. Sunitinib for Advanced Renal-Cell Carcinoma
4 Mar, 2021 | 08:33h | UTCNivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
M-A: Local salvage therapies after radiotherapy for prostate cancer
3 Mar, 2021 | 08:06h | UTCA Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) – European Urology (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Pleased to share the results of our "MASTER" systematic review and meta-analysis of local salvage therapies for radioreccurent PCa @EUPlatinum https://t.co/23hy1UtNm5
— Amar Kishan (@AmarUKishan) December 11, 2020
RCT: Extended vs. limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer
3 Mar, 2021 | 08:05h | UTCExtended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial – European Urology (link to abstract – $ for full-text)
Commentary: Extended pelvic lymph node dissection during RP does not appear beneficial – Urology Times
Commentary on Twitter
Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial#VisualAbstract https://t.co/7fAFlKmfTf@jeanlestingi @qdtrinh @RafaelFCoelho2 pic.twitter.com/es53WpXBFR
— European Urology (@EUplatinum) December 10, 2020
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update
21 Feb, 2021 | 21:47h | UTC
Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging
16 Feb, 2021 | 01:50h | UTCCommentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)
Commentary on Twitter
A handy infographic of our recently published research
Full paper is open access and free for all 🔬📜🙌
👉https://t.co/xDlz1A4kjR@eldredevans @JAMAOnc @EmilyD_stats @SageOfLondon1 @Connor_Urol @ImperialSandC @LondonProstate1 @Francy_lif @ProfPadhani @HemmySokhi pic.twitter.com/cEwSCv4NXy— Imperial Prostate (@IP_London) February 14, 2021
RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
15 Feb, 2021 | 00:36h | UTCLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib.
— NEJM (@NEJM) February 13, 2021
RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
15 Feb, 2021 | 00:34h | UTCEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma
15 Feb, 2021 | 00:32h | UTCA comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress
RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer
15 Feb, 2021 | 00:29h | UTC[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today